With a PhD in Tuberculosis Epidemiology and 16 years of experience, Christiaan Mulder has been contributing extensively to the field of TB prevention and care, and has expertise in research in both low- and high- TB burden countries.

Christiaan provides technical assistance to countries for national strategic planning and is a member of the WHO-EURO roster of consultants supporting WHO European region member states in optimizing their TB prevention and systematic screening activities.

Within KNCV, Christiaan currently leads the Prevention & Access team at KNCV Tuberculosis Foundation and serves as the organization’s Innovation Pathway Lead on Post-TB health and wellbeing. He focuses primarily on epidemiological and implementation research aimed to generate evidence and accelerate uptake of tuberculosis preventive treatment. Christiaan is a member of KNCV´s Institutional Ethical Review Board. He has led the Unitaid funded IMPAACT4TB project, overseeing the implementation of TPT regimens in Ethiopia, Indonesia, Malawi, and Tanzania. Christiaan also provides technical assistance for the design and implementation of drug resistance surveys, optimal screening and diagnostic algorithms (including Xpert MTB/RIF and CAD4TB).

 

Recent publications

1. Spruijt I, Verhage A, Procee F, Vrubleuskaya N, Mulder C, Akkerman O. Perceptions and clinical practices associated with post-TB health and well-being in the Netherlands. IJTLD Open. 1(10):480-482. October 1, 2024.

2. Salazar-Austin N, Bergman AJ, Mulder C, Tudor C, Mulatu F, Conradie G, Chaisson RE, Golub JE, Churchyard G, Bedru A and Kerrigan D. Improving access to tuberculosis preventive treatment for children in Ethiopia: designing a home-based contact management intervention for the CHIP-TB trial through formative research. BMC Health Serv Res 24, 1043. September 10, 2024

3. Kohler S, Achar J, Mulder C, Sitali N, Paul N. Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Global Health 20, 51. June 25, 2024.
4. Allwood B.W, Nightingale R, Agbota G, Auld S, Bisson G.P, Byrne A, Dunn R, Evans D, Hoddinott G, Gunther G, Islam Z, Johnston J.C, Kalyatanda G, Khosa C, Marais S, Makanda G, Mashedi OM, Meghji J, Mitnick C, Mulder C . et al. Perspectives from the 2nd International Post-Tuberculosis Symposium: mobilizing advocacy and research for improved outcomes . IJTLD OPEN, March 1, 2024, pp. 111-123(13)
5. De Groot LM , Shearer K, Sambani C, Kaonga E, Nyirenda R, Mulder C . Health care providers acceptance of default prescribing of TB preventive treatment for people living with HIV in Malawi: a qualitative study . BMC Health Serv Res. Jan 4, 2024.
6. Spruijt I, Erkens C, Greenaway C, Mulder C, Raviglione M, Villa S et al. Reducing the burden of TB among migrants to low TB incidence countries. Int J Tuberc Lung Dis. 2023 Mar 1;27(3):182-188.
7. Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, Lyakurwa D. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort. Trop Med Int Health. 2023 May;28(5):357-366.
8. Salazar-Austi N, Mulder C, Hoddinott G, Ryckman T, Hanrahan CF, Velen K, Chimoyi L, Charalambous A, Chihota, VN. Preventive Treatment for Household Contacts of Drug-Susceptible Tuberculosis Patients. Pathogens 2022, 11(11), 1258
9. Mitiku P, Scholten JN, Getachew M, Mulder C. 3HP nearly doubled the uptake of TB preventive treatment among PLHIV newly initiated on ART in Ethiopia. IJTLD. 2022; Apr 1;26(4):381-382.
10. Mulder C, Rupert S, Setiawan E, Mambetova E, Edo P, Sugiharto J, et al. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Glob Health. 2022;7(1).

 

read all the KNCV publications